Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $151.83 +1.56%
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.94, $0.77 better than the analyst estimate of $1.17. Revenue for the quarter came in at $811 million versus the consensus estimate of $766.85 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nucor projects Q3 2026 earnings above prior year, below estimates
- JLL (JLL) files mixed shelf
- McDonald’s said to plan value strategy overhaul to revive US sales growth
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
